Profile

Culture

Core team

Qualification

Technology

Cooperation

Clinical testing service: Tumor personalized liquid biopsy Lung cancer detection Gastric and colorectal cancer treatment target detection Female gynecological oncology Pan-cancerous solid tumor (multi-cancer) Chemotherapy guidance Hereditary tumor detection; Tumor personalized clinical testing Lung cancer detection Gastric and colorectal cancer treatment target detection Female gynecological oncology Immunity therapy Pan-cancerous solid tumor (multi-cancer) Chemotherapy guidance Hereditary tumor detection

Health checkup products: Rui Health; Ryan

Cutting-edge research services: Single cell sequencing; T cell immune library sequencing; New antigen detection; Tumor personalized science research; High-throughput multi-omics sequencing and analysis services

News

Knowledge

Recruitment

Staff style

APP download

WeChat

Tel: +86-571-89360709 E-mail: service@repugene.com
Address: 21-23, Health Valley, No. 1500, Wenyi West Road, Yuhang District, Hangzhou, Zhejiang, China
Copyright: Hangzhou Repugene Technology Co., Ltd. Powered by www.300.cn
浙ICP备16003170号

Hangzhou Repugene Technology Co., Ltd. is a high-tech advanced biomedical research and development enterprise with the team of Dr. Haigui.

core team

Chief Clinical Medicine Consultant Professor Wang Yi

Release time：

2019/01/19 17:20

Page view

[Abstract]:

Chief clinical medical consultant
Professor Wang Yi
Double Ph.D. in Medicine and Molecular Biology, Arkansas School of Medicine, USA

Chief clinical medical consultant

Professor Wang Yi

Double Ph.D. in Medicine and Molecular Biology, Arkansas School of Medicine, USA

Director of the Department of Gastrointestinal Oncology, Cancer Center, St. Louis University, St. Louis, USA, Director of the New Drug Research Center, Associate Professor of Oncology.

Member of the American Cancer Clinical Trial Alliance gastrointestinal tumor (ALLIANCEGI) committee, member of the American Pancreatic Cancer Society, member of the American Cancer Research Association

Hosted a phase III clinical trial of nanoliposomal irinotecan for advanced pancreatic cancer, which enabled the drug to be successfully approved.

Market Operations Consultant Mr. Wan Jiang

Chief Medical Consultant Dr. Mao Li